Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
Kirschbrown WP, Kågedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, von Minckwitz G, Bines J, Garg A. Kirschbrown WP, et al. Among authors: girish s. Cancer Chemother Pharmacol. 2019 Jun;83(6):1147-1158. doi: 10.1007/s00280-019-03826-1. Epub 2019 Apr 11. Cancer Chemother Pharmacol. 2019. PMID: 30976844 Free PMC article. Clinical Trial.
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Gupta M, Lorusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, Joshi A, Girish S. Gupta M, et al. Among authors: girish s. J Clin Pharmacol. 2012 May;52(5):691-703. doi: 10.1177/0091270011403742. Epub 2011 Sep 27. J Clin Pharmacol. 2012. PMID: 21953571 Clinical Trial.
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A. Girish S, et al. Cancer Chemother Pharmacol. 2012 May;69(5):1229-40. doi: 10.1007/s00280-011-1817-3. Epub 2012 Jan 20. Cancer Chemother Pharmacol. 2012. PMID: 22271209 Free PMC article. Clinical Trial.
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M. Bender BC, et al. Among authors: girish s. Cancer Chemother Pharmacol. 2012 Oct;70(4):591-601. doi: 10.1007/s00280-012-1934-7. Epub 2012 Aug 12. Cancer Chemother Pharmacol. 2012. PMID: 22886072 Clinical Trial.
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin JY. Lu D, et al. Among authors: girish s. Cancer Chemother Pharmacol. 2014 Aug;74(2):399-410. doi: 10.1007/s00280-014-2500-2. Epub 2014 Jun 18. Cancer Chemother Pharmacol. 2014. PMID: 24939213 Free PMC article.
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Gupta M, Wang B, Carrothers TJ, LoRusso PM, Chu YW, Shih T, Loecke D, Joshi A, Saad O, Yi JH, Girish S. Gupta M, et al. Among authors: girish s. Clin Pharmacol Drug Dev. 2013 Jan;2(1):11-24. doi: 10.1002/cpdd.9. Epub 2013 Feb 26. Clin Pharmacol Drug Dev. 2013. PMID: 27121556
115 results